(BW) VIMRx Reports Clinical Trial Results For VIMRxyn for AIDS

(BW) VIMRx Reports Clinical Trial Results For VIMRxyn for AIDS

BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 -

WILMINGTON, Del.--(BUSINESS WIRE)--September 19, 1996--VIMRx Pharmaceuticals Inc. (Nasdaq SmallCap:VMRX) has announced that results from its Phase I/Phase II clinical trial in Thailand indicate that a well tolerated oral dose with no untoward toxicity or cutaneous photosensitivity has been identified as 0.05 mg/kg of VIMRxyn, synthetic hypericin. At this dose level, VIMRxyn was administered once daily for 28 days to 12 HIV infected patients.

Anti-HIV activity, as determined by a reduction in viral load, was quantitated using polymerase chain reaction (PCR) to measure plasma HIV RNA. Maximum changes from baseline values observed for viral load at any time point among the patients dosed at 0.05 mg/kg ranged from essentially no change to a 1.50 log (97%) reduction, with a trend for larger decreases observed in those patients with higher baseline viral load values. VIMRx CEO Richard L. Dunning said that additional clinical trials involving longer dosing regimens and use of VIMRxyn in combination with other anti-HIV drugs will be necessary to evaluate the clinical efficacy of VIMRxyn in more detail.

VIMRx, based in Wilmington, Delaware, specializes in therapies to fight viral and retroviral diseases, as well as cancer. It has exclusive worldwide rights to develop VIMRxyn. Additional efforts are underway on the development of VIMRxyn for the treatment of brain cancer (malignant glioma) and chronic hepatitis C, as well as for use in improving safety of blood supplies.

NOTE TO INVESTORS AND EDITORS: VIMRx's press releases are available on the Internet through BusinessWire's web site at http://www.businesswire.com/cnn/vmrx.htm. The releases also are available at no charge through BusinessWire's fax-on-demand service at 800-411-8792.

CONTACT: Walter G. Montgomery or Mary Ann Dunnell 212/484-6721

Keywords: CLINICAL TRIAL; HYPERICIN; HIV; HEPATITIS

Copyright (c) 1996/BUSINESS WIRE. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854.
960919
BW960915

Copyright © 1996 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.

Always watch for outdated information. This article first appeared in 1996. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1996. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .